Log in with your email address username.

×

[Articles] Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

Significant improvement in objective response lasting at least 4 months was seen with brentuximab vedotin versus physician’s choice of methotrexate or bexarotene.

email